The Union Cycliste Internationale (UCI) announces that Belarusian rider Kanstantsin Siutsou was notified of an Adverse Analytical Finding (AAF) of Erythropoietin in a sample collected in the scope of an out-of- competition control on 31 July 2018.
The control was planned and carried out by the Cycling Anti-Doping Foundation (CADF), the independent body mandated by the UCI, in charge of defining and implementing the anti-doping strategy in cycling.
The rider has the right to request and attend the analysis of the B sample.
In accordance with UCI Anti-Doping Rules, the rider has been provisionally suspended until the adjudication of the affair.
In the Anti-Doping Database we have registered 197 cases where a cyclist has tested positive for EPO. Since 2016 there has been no positive cases in cycling reported by UCI involving EPO. There has - how ever - been a rise in the use of CERA - the third generation of EPO. In 2016 we only registered two cases involving CERA in cycling. In 2017 this number exploded to 11. In 2018 there has so far been reported two cases involving CERA by the UCI.